GAO Questions FDA’s Post-Marketing Oversight for Drugs Approved via Expedited Programs
A survey conducted by the Government Accountability Office (GAO) found that FDA does not have robust processes to oversee the safety of drugs approved under expedited programs. There are 4 programs under which new drugs can be approved by FDA under reduce testing burden and shorter review times. These programs are priority review, breakthrough therapy designation, accelerated … Read more